Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Jacqueline S. Garcia, Haesook T. Kim, Jennifer Brock, H. Moses Murdock, Mahasweta Gooptu, Vincent T. Ho, Roman M. Shapiro, Christopher J. Gibson, Amar H. Kelkar, Corey S. Cutler, Denbaa Bat-Erdene, Jeremy Ryan, Anna Bosch-Vilaseca, Anthony G. Letai, Jerome Ritz, Coleman Lindsley, Robert J. Soiffer, Joseph Antin

Blood (2024) 144 (Supplement 1): 1045.

https://doi.org/10.1182/blood-2024-194170

Published: 2024

Journal Articles

Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Blood (2024) 144 (Supplement 1): 4580.

https://doi.org/10.1182/blood-2024-198284

Published: 2024

Journal Articles

Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 4261.

https://doi.org/10.1182/blood-2024-203683

Published: 2024

Journal Articles

Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 48.

https://doi.org/10.1182/blood-2023-189156

Published: 2023

Journal Articles

Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Blood (2022) 140 (Supplement 1): 917–919.

https://doi.org/10.1182/blood-2022-157611

Published: 2022

Journal Articles

Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134947

Published: 2020

Journal Articles

Dynamic BH3 Profiling As Pharmacodynamic Biomarker for the Activity of BH3 Mimetics

Rongqing Pan, PhD, Youzhen Wang, Shumei Qiu, Jeremy Ryan, Ensar Halilovic

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-138916

Published: 2020

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

Understanding Apoptotic Blocks in "Double Hit" and Other Non-Hodgkin Lymphomas By BH3 Profiling

Claudia M Wever, PhD, Dominique Geoffrion, BSc, Pierre Sesques, MD, Liliana Stoica, Josee Hebert, MD, Jeremy Ryan, Anthony Letai, MD PhD, Nathalie A Johnson, MDPhD

Blood (2017) 130 (Supplement 1): 1471.

https://doi.org/10.1182/blood.V130.Suppl_1.1471.1471

Published: 2017

Journal Articles

Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML

Qi Zhang, MD PhD, Lina Han, MD PhD, Ce Shi, MD PhD, Rongqing Pan, MS, Man Chun John MA, PhD, Jeremy Ryan, PhD, Stephen E Kurtz, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Helen Ma, MS, Michael Andreeff, MD PhD, Yingchang Mi, MD PhD, Jeffrey W. Tyner, PhD, Joel Leverson, Anthony Letai, MD PhD, Richard Eric Davis, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 101.

https://doi.org/10.1182/blood.V128.22.101.101

Published: 2016

Journal Articles

BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics

Cyrille Touzeau, MD, Jeremy Ryan, SM, Philippe Moreau, MD, Triona Ni Chonghaile, PhD, Steven Le Gouill, Paul G. Richardson, Kenneth C. Anderson, Martine Amiot, PhD, Anthony G. Letai, MD PhD

Blood (2014) 124 (21): 417.

https://doi.org/10.1182/blood.V124.21.417.417

Published: 2014

Journal Articles

Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells

Kazuyuki Murase, MD PhD, Haesook T. Kim, PhD, Masahiro Hirakawa, MD PhD, Tiago Reis Matos, MD, Yutaka Kawano, MD PhD, Jeremy Ryan, SM, Ken-Ichi Matsuoka, MDPhD, John Koreth, MBBS, DPhil, Robert J Soiffer, MD, Anthony G. Letai, MD PhD, Junji Kato, MD PhD, Jerome Ritz, MD

Blood (2014) 124 (21): 1414.

https://doi.org/10.1182/blood.V124.21.1414.1414

Published: 2014

Journal Articles

Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia

Matthew S. Davids, MD, Jing Deng, PhD, Jeremy Ryan, SM, Stacey M. Fernandes, Jennifer R. Brown, Anthony G. Letai, MD PhD

Blood (2014) 124 (21): 1940.

https://doi.org/10.1182/blood.V124.21.1940.1940

Published: 2014

Journal Articles

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Blood (2014) 124 (21): 3713.

https://doi.org/10.1182/blood.V124.21.3713.3713

Published: 2014

Journal Articles

Low-Dose IL-2 Induces Bcl2 Expression and Resistance To Apoptosis In CD4 Regulatory T Cells

Kazuyuki Murase, MD, PhD, Yutaka Kawano, MD, PhD, Jeremy Ryan, SM, Ken-ichi Matsuoka, MD, PhD, Gregory Bascug, BS, Sean McDonough, MS, Robert W Smith, BS, Kristen Cowens, Suzan Lazo-Kallanian, John Daley, PhD, John Koreth, MBBS, DPhil, Robert J. Soiffer, MD, Anthony Letai, MD, PhD, Jerome Ritz, MD

Blood (2013) 122 (21): 3475.

https://doi.org/10.1182/blood.V122.21.3475.3475

Published: 2013

Journal Articles

BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia

Leah Hogdal, Daniel J. DeAngelo, MD, Ph.D, Richard M. Stone, MD, Verena I. Gaidzik, MD, Donna Bucci, Konstanze Döhner, MD, Guido Marcucci, MD, Jeremy Ryan, SM, Anthony Letai, MD, PhD

Blood (2013) 122 (21): 238.

https://doi.org/10.1182/blood.V122.21.238.238

Published: 2013

Journal Articles

Differential Effects of TCR Stimulation and IL-2 On Apoptotic Pathways in CD4 Regulatory T Cells Compared to Conventional CD4 T Cells and CD8 T Cells

Kazuyuki Murase, MD, PhD, Yutaka Kawano, MD, PhD, Jeremy Ryan, Ken-ichi Matsuoka, MD, PhD, Gregory Bascug, BS, Sean McDonough, MS, Robert W Smith, BS, Suzan Lazo-Kallanian, John Daley, PhD, Matthew S. Davids, MD, Anthony G. Letai, MD, PhD, Jerome Ritz, MD

Blood (2012) 120 (21): 3280.

https://doi.org/10.1182/blood.V120.21.3280.3280

Published: 2012

Journal Articles

Apoptotic Pathways of Human Regulatory T Cells in Chronic Graft Versus Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Kazuyuki Murase, MD, PhD, Yutaka Kawano, MD, PhD, Jeremy Ryan, Ken-ichi Matsuoka, MD, PhD, Gregory Bascug, BS, Sean McDonough, MS, Robert W Smith, BS, Suzan Lazo-Kallanian, John Daley, PhD, John Koreth, MBBS, DPhil, Robert J. Soiffer, MD, Anthony G. Letai, MD, PhD, Jerome Ritz, MD

Blood (2012) 120 (21): 225.

https://doi.org/10.1182/blood.V120.21.225.225

Published: 2012

Journal Articles

Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index

Triona Ni Chonghaile, PhD, Kristopher Sarosiek, PhD, Jeremy Ryan, Vicki Del Gaizo Moore, PhD, Yu-Tzu Tai, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Richard M. Stone, MD, Daniel J DeAngelo, MD, PhD, Constantine S. Mitsiades, MD, PhD, Stephen E. Sallan, MD, Michelle Hirsch, MD PhD, Lewis B. Silverman, MD, Ruben Carrasco, MD, PhD, Anthony G. Letai, MD, PhD

Blood (2011) 118 (21): 1442.

https://doi.org/10.1182/blood.V118.21.1442.1442

Published: 2011

NARROW

Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia

Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia

Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies

Dynamic BH3 Profiling As Pharmacodynamic Biomarker for the Activity of BH3 Mimetics

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Understanding Apoptotic Blocks in "Double Hit" and Other Non-Hodgkin Lymphomas By BH3 Profiling

Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML

BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics

Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells

Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Low-Dose IL-2 Induces Bcl2 Expression and Resistance To Apoptosis In CD4 Regulatory T Cells

BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia

Differential Effects of TCR Stimulation and IL-2 On Apoptotic Pathways in CD4 Regulatory T Cells Compared to Conventional CD4 T Cells and CD8 T Cells

Apoptotic Pathways of Human Regulatory T Cells in Chronic Graft Versus Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only